AJMC urges lung screening overhaul

AJMC reported on August 5 that a new review is pressing lung-cancer screening programs to move beyond smoking history alone when deciding who should receive low-dose CT scans. The review, as described by AJMC, argues that environmental exposures, family history and artificial-intelligence risk models should be added to screening decisions. The proposal centers on multi-factor risk stratification rather than smoking-only rules. AJMC said the aim is to better identify people most likely to benefit while limiting unnecessary follow-up after screening. ### Why are smoking-history rules under pressure? The U.S. Preventive Services Task Force in 2021 expanded eligibility for annual lung-cancer screening to adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years, according to JAMA Internal Medicine. But the same commentary said pack-year history can be hard to capture accurately because it depends on patient recall and consistent documentation in medical records. (ajmc.com) JAMA Internal Medicine said those documentation limits have fueled interest in alternatives to current eligibility criteria. The commentary, published online June 29, 2026, said newer approaches are being evaluated for how they balance effectiveness — averting lung-cancer deaths — against efficiency, including avoiding screening people least likely to benefit. (jamanetwork.com) ### What would a broader risk model include? AJMC said the review calls for screening decisions to incorporate environmental exposures and family history alongside smoking behavior. ScienceDirect and Nature both describe the same broader shift in the field: risk models that add factors such as secondhand smoke exposure, occupational or environmental exposures, comorbidities, clinical variables and, in some cases, genetic information. (jamanetwork.com) Nature said low-dose CT screening reduces lung-cancer mortality in high-risk populations defined by age and smoking history, but uptake remains low and researchers are exploring more precise ways to identify risk. AJMC’s report places AI-driven risk models inside that effort, presenting them as tools that could refine who is selected for screening. (sciencedirect.com) ### What problem are these changes supposed to solve? Low-dose CT screening can save lives, but broader eligibility can also increase the number of scans and downstream workups. JAMA Internal Medicine said alternative eligibility thresholds show trade-offs between maximizing deaths averted and minimizing unnecessary screening examinations. (nature.com) AJMC said the review argues that multi-factor stratification could improve candidate selection and reduce unnecessary follow-ups. In practice, that means shifting the question from whether a person meets a single smoking threshold to whether several risk factors together make screening more likely to help than harm. That framing is an inference from the review summary and the JAMA commentary on effectiveness-versus-efficiency trade-offs. (jamanetwork.com) ### Where do laboratorians fit into a screening story centered on CT scans? The AJMC report is about screening policy, but the operational effects extend beyond radiology. If eligibility decisions rely more on documented exposures, family history and algorithmic risk estimates, laboratories and diagnostics teams may face more pressure to support pretest probability assessments, document assay limits clearly and explain how test performance changes across different-risk populations. (ajmc.com) That is an inference drawn from the review summary and the broader move toward risk-stratified screening described in AJMC, Nature and JAMA Internal Medicine. ScienceDirect said current evidence increasingly points to models that move beyond age and smoking history alone. For clinical teams, that raises familiar questions about sensitivity, specificity and how to defend follow-up decisions when a patient falls outside older smoking-based criteria. ### What happens next? AJMC’s August 5 report is the immediate public account of the review and its recommendations. (ajmc.com) Any change to U.S. screening practice would still depend on how guideline-setting groups and health systems assess evidence for broader risk models against existing USPSTF-style criteria. (sciencedirect.com)